

You are a company believing in open innovation ?

Looking for a new product with high added value ?

SATT Paris-Saclay invests **k€430** in the development of a **probiotic approach for the treatment of cancer in animals**. We are looking for a strategic partnership to industrialize and commercialize it !

LUCKY

#Probiotic

#Cancer

#Veterinary

#QualityOfLife

#AntiInflammatory

#AntiProliferative

—● **Technology**

- ▶ **New strain** of *Lactobacillus brevis* used as probiotic
- ▶ **Anti-inflammatory and anti-proliferative activities** more potent compared to other strains described
- ▶ **Possible efficiency** for different types of canine cancers (lymphoma, colo-rectal...).

—● **Use case**

- ▶ **Significant progression** of cancer cases in dogs and cats (about 1 in 4 dogs will develop cancer in their lifetime)
- ▶ **Existing curative or palliative treatment options** are few or not very accessible (cost, limited availability, side effects and constraints)
- ▶ **Important unmet clinical need** for the development of new cancer treatment that are less invasive and that best preserve the quality of life of the animal.

—● **Benefits**

- ▶ **Non-invasive treatment** preserving a good quality of life for the animal
- ▶ **Alternative or add-on to cytotoxic treatments** in order to optimize their efficacy.

Discover the project

///// **The advantages of the project**

- ▶ « Add-on » or alternative to common treatment options for animal cancer and tumor
- ▶ Non-invasive approach
- ▶ Preserving a good quality of life of the animal.

—● **Working with SATT Paris-Saclay :**

SATT Paris-Saclay business model is based on a virtuous mechanism of sharing the revenues generated by the exploitation of research results protected by **1 patent**. The company will benefit from an **exclusive licence** in return for the payment of reduced royalties (% of turnover).

Project assets : "NEW PROBIOTIC STRAIN OF LACTOBACILLUS BREVIS", WO2019234076.